



Universiteit
Leiden
The Netherlands

Juvenile Idiopathic Arthritis: Towards Improving Clinical Care

Hissink Muller, P.

Citation

Hissink Muller, P. (2019, October 31). *Juvenile Idiopathic Arthritis: Towards Improving Clinical Care*. Retrieved from <https://hdl.handle.net/1887/80001>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/80001>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/80001> holds various files of this Leiden University dissertation.

Author: Hissink Muller, P.

Title: Juvenile Idiopathic Arthritis: Towards Improving Clinical Care

Issue Date: 2019-10-31

7

Participation in a single-blinded Pediatric Therapeutic Strategy Study for Juvenile Idiopathic Arthritis: Are Parents and Patient-participants in Equipoise?

Petra CE Hissink Muller MD, Bahar Yildiz MD, Cornelia F Allaart MD PhD,
Danielle MC Brinkman MD PhD, Marion van Rossum MD PhD,
Lisette WA van Suijlekom-Smit MD PhD, J Merlijn van den Berg MD PhD,
Rebecca ten Cate MD PhD, Martine C de Vries MD PhD

Published in BMC Medical Ethics. 2018 Dec 20;19(1):96

ABSTRACT

Background: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks. Ideally, this equipoise is also present in patient-participants. In pediatrics, data on equipoise are lacking. We hypothesize that 1) lack of equipoise at enrolment among parents may reduce recruitment; 2) lack of equipoise during participation may reduce retention in patients assigned to a less favoured treatment-strategy.

Methods: We compared preferences of parents/patients at enrolment, documented by a questionnaire (phase 1), with preferences developed during follow-up by an interview-study (phase 2) to investigate equipoise of child-participants and parents in the BeSt-for-Kids-study (NTR 1574). This trial in new-onset Juvenile Idiopathic Arthritis-patients consists of three strategies. One strategy comprises initial treatment with a biological disease-modifying-antirheumatic-drug (DMARD), currently not standard-of-care. Semi-structured interviews were conducted with 23 parents and 7 patients, median 11 months after enrolment.

Results: Initially most parents and children were not in equipoise. Parents/patients who refused participation, regularly declined due to specific preferences. Many participating families preferred the biological-first-strategy. They participated to have a chance for this initial treatment, and would even consider stopping trial-participation when not randomized for it. Their conviction of superiority of the biological-first strategy was based on knowledge from internet and close relations. According to four parents, the physician-investigator preferred the biological-first-strategy, but the majority (n = 19) stated that she had no preferred strategy. In phase 2, preferences tended to change to the treatment actually received.

Conclusions: Lack of equipoise during enrolment did not reduce study recruitment, mainly due to the fact that preferred treatment was only available within the study. Still, when developing a trial it is important to evaluate whether the physicians' research question is in line with preferences of the patient-group. By exploring so-called 'informed patient-group'-equipoise, successful recruitment may be enhanced and bias avoided.

In our study, lack of equipoise during trial-participation did not reduce retention in those assigned to a less favoured option. We observed a change for preference towards treatment actually received, possibly explained by comparable outcomes in all three arms.

Key words: randomization, equipoise, pediatric rheumatology, clinical trial, informed consent

BACKGROUND

It is an ethical requirement that physician-investigators provide research-participants the best treatment available in randomized controlled trials (RCT)¹⁻³. In a clinical trial comparing different treatment strategies there should be uncertainty regarding preferred treatment option considering therapeutic efficacy and safety¹⁻⁴. This is called equipoise. 'Individual equipoise' implies that the *individual* physician-investigator must possess this genuine uncertainty¹. Affected by preliminary results during a trial, a physician-investigator could develop a preference which might lead to a perceived conflict whether the best treatment known is actually provided. Therefore, Freedman described 'clinical equipoise' as genuine uncertainty in the *medical expert community* instead of genuine uncertainty in the individual physician-investigator¹. Clinical equipoise allows the physician-investigator to collect evidence to convince the expert community of either superiority. Critics on clinical equipoise argue that this concept needs to be transformed to adapt to forward modern health care: if the potential social value of a study is relevant and participants are not exposed to excessive net risks, clinical equipoise can be amended^{5, 6}. Kimmelman questions whether equipoise should be rethought as a prima facie principle rather than an absolute one⁷ and we agree on that. Miller et al even question the necessity of equipoise⁸.

Literature suggests that not only the medical expert community should be in equipoise but also patient-participants (and their parents, if children are concerned)^{8, 9}.

In pediatrics, experience with clinical equipoise is limited^{10, 11}. In pediatric oncology, parental and physician equipoise has been scarcely studied^{12, 13}. Difficult protocols, strong emotions and the parents' dependency on their child's physician are reasons for often lacking parental equipoise. In pediatric rheumatology, treatment preferences among physicians have been studied by Huggle et al¹⁴ revealing that availability and funding influenced physicians' choices. A discrete choice experiment explored parents preferences in juvenile idiopathic arthritis in daily clinical care¹⁵. Parents have strong preferences for treatments that reduce pain and improve daily functioning, regardless of side effects. With increasing disease duration, parents preferences focused on therapeutic effectiveness. Little is known about patient-participant-equipoise or parent-equipoise^{9, 16, 12} in pediatric clinical research on chronic diseases. More insight in this equipoise is particularly important when considering the inherent vulnerability of children in research¹⁷.

METHODS

Aims

In this study we aimed to evaluate (1) the preferences of Juvenile Idiopathic Arthritis (JIA) patients aged 12 years and older, and their parents for a certain treatment strategy in the setting of a randomized clinical trial, and (2) the influence of the informed consent procedure on these preferences.

Context BeSt for Kids study

The trial concerned *the BeSt for Kids study* (Dutch Trial Register NTR 1574), a multicenter, randomized, single blinded two year follow-up clinical trial comparing time- to-inactive disease and time-to-flare in selected categories of newly diagnosed JIA patient-participants. In this study patient-participants (age between 2-16 years) with a maximum of 18 months of complaints and 1) oligoarticular JIA 2) Rheumatoid Factor (RF) negative polyarticular JIA and 3) Juvenile Psoriatic Arthritis, (6) with active disease requiring treatment with a disease modifying antirheumatic drug (DMARD) according to the treating pediatric rheumatologist were randomized in three treatment strategies. These strategies are

1. initial monotherapy with sulfasalazine or methotrexate,
2. initial combination therapy with methotrexate and prednisone bridging
3. initial combination therapy with methotrexate and etanercept.

In the study protocol subsequent steps to reach inactive disease are dictated in case of insufficient response in all three arms (supplementary file 1).

Data on efficacy of the different individual DMARD is available in literature¹⁸⁻²⁰. No data existed before and during inclusion on the superiority of either of those strategies.

The treatment was single-blinded: the periodic assessment of disease activity was performed by a physiotherapist, unaware of the allocated treatment, but patient and physician were not blinded.

The informed consent procedure for inclusion in the BeSt for Kids study consisted of at least one visit to the outpatient clinic, with an oral explanation by the attending physician and the research nurse and complementary written information. In addition to the patient-subjects information form (PIF) (supplementary file 2) , all newly diagnosed patients with juvenile idiopathic arthritis are referred to www.printo.it for general information on juvenile idiopathic arthritis. Besides that, patients and parents had several days to week(s) between receiving written PIF and actual enrolment.

Design equipoise study

Phase 1 (questionnaire): When parents and children (aged 12 years and older) consented to participate in the trial, they were randomized. Subsequently the physician completed the Case Report Form which included a questionnaire asking parents and patients for their preferred strategy before actual allocation to the strategy (supplementary file 3). To diminish bias by only asking participating parents and patients we additionally collected the reasons for not participating in the study.

Phase 2 (interview study): We conducted an interview study with parents and patient-participants aged 12 years and older participating in the BeSt for Kids study which was designed after of the onset of the study. Parents and patient-participants were informed of the interview by a letter asking them to participate in the interview study. All patients enrolled in the study at that time point (n=29) were contacted by telephone for participation, which lead to an appointment for an interview with a short questionnaire. To facilitate families, the actual interview was held in the hospital or at home by choice. One-to-one, semi-structured interviews were conducted with the parents and patient-participants (supplementary file 4).

We choose the age of 12 years for patient interviews since in the Netherlands by law children from the age of 12 years old are actively involved in their healthcare related decisions in consultation with their parent(s) or guardian(s).

Interview Procedure and Analysis

All parents and patient-participants were interviewed by researcher B.Y. Interview topics and questions were formulated after evaluation of the relevant literature. Topics were: 1 Evaluation of the Informed consent procedure, 2 Preference for treatment strategy, 3 Comments on preference, 4 Impression of physicians' preference and 5 Main reasons for participation in BeSt for Kids study. Interviews contained closed-ended as well as open-ended questions. Using the latter, participants could elaborate on their answers on closed-ended questions. Interviews lasted between 20 and 45 minutes.

The interviews were recorded and transcribed verbatim. Data analysis of the interviews was based on the constant comparative method^{21, 22}. One of the researchers encoded the full transcripts manually by identifying and labeling discrete units of texts which refer to one or more concepts relevant to the study. Through comparison across transcripts, open codes were developed into higher order themes to provide a framework for coding subsequent transcripts. P.H.M. and M.d.V. coded a random sample of the interviews to check for consistency and adequacy of the framework. When no new thematic content was found in the parent interviews, subject enrolment was stopped. This process, called

thematic saturation, is a well-described qualitative method to avoid unnecessarily large and repetitive data sets^{23, 24}.

Finally, representative quotations from parents and physicians were chosen to demonstrate the themes identified.

Setting

The BeSt for Kids and the current project were approved by the Institutional Review Board at Leiden University Medical Center and written informed consent was obtained from all participants before enrolment.

RESULTS

Phase 1 Questionnaire: Preference at inclusion in the BeSt for Kids study

During recruitment, we have received information on reasons for refusal in 15 out of 36 refusals (table II). In total 94 children were randomized in the BeSt for Kids study.

All parents and children aged 12 and older were asked during enrolment in the BeSt for Kids study, before randomization, whether they hoped to be assigned to a particular treatment strategy. At the start 46% of parents of all enrolled patient-participants (n=94) expressed to have no preference, 34% hoped for assignment to strategy 3 (initial etanercept with methotrexate) and 7% hoped against assignment to strategy 3. Primary aversion was highest for the second strategy (25%) due to a dislike of prednisone (data not shown). To compare, reasons for refusal to participate in the study were documented in 15/36(42%) and are summarised in table II. Multiple reasons were expressed, ranging from strong preference to dislike for a particular arm. Six out of 36 (17%) expressed explicit preferences or dislike of arm 1 or arm 3.

Table 1 | Summary of patients/parents who refused to participate in the BeSt for Kids study with reasons for refusal

Number of patients who refused to participate Known Reason for refusal of trial participation	n=36 n=15 (42%)
Preference for arm 1	1
Preference for arm 3	1
Fear in general	1
Do not want to randomize at all	2
Do not want to receive prednisone or injections	2
Do not want to receive arm 3	2
Too busy to participate	2
Don't feel like it	2
No reason mentioned when asked	2

Phase 2: Interview study

Figure 1 shows the recruitment of parents and patient-participants in our interview study. Twenty-nine patients were approached for the interview-study, finally 23 interviews were conducted. Parents had a mean age of 40.0 years (range 32-51 years) and patient-participants 14.3 years (range 12-17 years). All participants were Dutch speaking. Characteristics of parents and patient-participants are given in Table I. Between inclusion in the BeSt for Kids study and the interview was a period of mean 12 (3-19) months.




Figure 1 | Recruitment of parents and patients

The concepts that were identified in the qualitative analysis resulted in a framework that comprises the following three themes which will be discussed separately:

- I Participation is not without consequences.
- II The conviction of superiority of the 'experimental' strategy.
- III Participation is in the best interest of the child.

Theme 1: Non-participation or withdrawal is not without consequences

The majority of parents and children was well aware of the study design. Results indicated no differences between parental and patient-participants' understanding concerning study name, duration, aim and number of treatment strategies. Although almost all participants (parents n=23, patient-participants n=6) knew that they were allowed to withdraw from the study at all times, seven parents and four patient-participants believed that stopping the trial would have consequences for the treatment in terms of less quality and quantity of the patient-participant care.

(Parent 8) Sure it has consequences. This means he is not being looked after [...]

(Parent 18) Now she gets such good care. That would be less; there would be less time and less checkups.

Two parents and three patient-participants argued that it would have consequences because initial treatment with etanercept is not covered by insurance companies outside the trial.

(Parent 19) Yes I think so. If you stop then you receive no further medication.

(Patient-participant 17) It could be that the insurance company requires you to pay for the drugs.

(Patient-participant 23) Because if I stop it has consequences for my treatment. Because I could never get this treatment by the insurance.

Theme 2: The conviction of superiority of the experimental strategy

All parents (n=23) expressed that they had a preference for a particular treatment strategy. Fourteen parents (61%) preferred the third strategy (initial etanercept with methotrexate) whereas 3 (13%) preferred the first strategy (initial sulfasalazine or methotrexate), one parent preferred the second strategy (initial methotrexate and prednisone bridging), one parent preferred the first or second strategy and four (17%) preferred a non-prednisone strategy.

Five of seven patient-participants had a preferred strategy. Three of them preferred initial etanercept with methotrexate (third strategy) and two preferred a non-prednisone strategy. Two of the patient-participants had no preference.

Generally, as main explanation for their preference for the 3rd strategy (initial etanercept with methotrexate) parents and patient-participants stated that they believed it is the best treatment for JIA given the results of previous studies²⁵⁻²⁸.

(Patient-participant 23) I also wanted that drug (etanercept), even though we did not know the side effects. Still, if you hear that it works very well and that the arthritis completely disappears from your joints, and therefore it is the best drug, then it seems obvious to me that you would want that.

(Parent 3) At one moment I read on the internet an experience by a mother who said she finally got her teenage daughter back, this was not the crucial reason but at that moment it confirmed my gut feeling.

(Parent 18) Well we have been searching quite a lot on the internet and it just gives reasonably good results as far as they presently know.

Parents and patient-participants indicated that these beliefs were mainly based on knowledge they had gained through the internet and from experiences in their environment. For both parents and patient-participants reluctance to prednisone was due to well-known side-effects, mainly gaining weight.

(Patient-participant 19) What I didn't want was prednisone, actually. That's because my mother had to use it for a long time and I have seen what it does, it has a lot of severe side effects.

The majority of parents (n=19) mentioned that the physician did not express a preferred treatment strategy. Four parents stated that the physician preferred etanercept-first strategy.

(Parent 6) The physician had no preference. She indicated that she was very curious about what the outcomes of the study will be.

(Parent 9) Yes, that new medicine. That's what she really said. She literally said that they would like to give it to us. But that simply couldn't, because of the study and because insurance companies do not want to pay.

(Parent 14a) I thought that the physician absolutely had no preference at all.

(Parent 16) Because of course, I didn't know it yet, we were confronted with a diagnosis that really was unexpected. [...] So I had the impression that they were very enthusiastic about this new drug, and that the study gave us the opportunity to get it earlier.

One of the patient-participants thought that the physician preferred initial treatment with etanercept. One did not remember and five recalled that the physician did not have a preference.

Theme 3 Participation is in the best interest of the child

Although some families stated that they (also) participated in the BeSt for Kids study to help the good cause of research and therefore to support the next generations of JIA patients (n=6 parents), many families expressed personal reasons to participate.

(Parent 4) [...] It was more the extra attention [...] However, also a little bit for the good cause, of course, that other patients could benefit from it as well in the long term.

Seven parents joined the study because they assumed that in participating, their child would be more closely observed. Parents also participated for the best prospect of their child (n=5), hoping that joining the study was the best they could do. Five parents stated that their reason for participation was to have the opportunity for initial treatment with etanercept (strategy 3). One mother even expressed that she would have withdrawn from the trial if her child had not randomized in their preferred strategy.

(Parent 23), Had I drawn strategy 2, I would have immediately stopped. Then I would have chosen my own direction with my child, off course in consultation with the physician In that case I would not want to participate in the study, and then you should have to work with the available resources.

(Parent 5) [...]Of course there are many benefits as a result of taking part...

Patient-participants also joined the study because of a chance for initial treatment with etanercept (strategy 3)(n=3).

(Patient-participant 23) I believe that our main goal was that we could get the really good medication.

Two patient-participants only mentioned their wish to recover (n=2) without giving another reason for participation. Two patient-participants chose to participate for the good cause of research.

Changing preferences

When comparing the results from phase 1, before randomization, to the results during the interview (phase 2), half of the parents (11/23) showed a different preference in the

interview compared to their opinion at enrolment, from which 6 out of 11 changed to preference of the actual enrolled treatment strategy, mainly increasing preference for arm 1 and arm 3. Eight out of 23 (36%) had a persistent preference for strategy 3 (Supplementary file 5 Table III and IV).

DISCUSSION

The results of our interview study demonstrate that at enrolment (phase 1) many parents and children in the BeSt for Kids study are not in equipoise, because most of them hold the conviction that strategy 3, initial combination therapy with methotrexate and etanercept, is medically superior to the other strategies, as described in theme 2. In the majority of parents this is not caused by an assumed preference of the physician-investigator but by information on the various treatment possibilities obtained from other sources.

Aversion for prednisone was based on fear for possible side-effects, whereas information on etanercept appeared to focus more on the efficacy and less on possible (future) side effects. This result is consistent with previous results in the BeSt-trial in rheumatoid arthritis patient-participants²⁹.

This is an evaluation of parents' preferences for treatment strategies by a questionnaire at enrolment (phase 1) as well as by interviews several months into the different treatment strategies (phase 2). When comparing results of the preferences at the two time points we conclude that parents increasingly preferred initial combination therapy with etanercept and methotrexate and disliked taking prednisone. Having a preferred strategy in general increased from 62% at enrolment to 100% of parents during the study period. This difference can be explained by the fact that the interview took place almost a year after study enrolment so that perception can be modified by experience. Initially preferences focused on fear of side effects of prednisolone and suspected superiority of the initial etanercept (arm 3). In phase 2 preferences shifted to mainly arm 1 and arm 3, often the actual strategy children received. Parents and children by then seemed to focus on effectiveness of the therapy received, as was described previously¹⁵.

Parents have many motivations when deciding whether or not to let their child enter a randomized clinical trial. They will not easily agree on randomization because an ethics committee has approved the study^{30, 31}. The primary responsibility of parents is to act in (what they think is) the best interest of the child, and the choice to enter a trial is based both on 'objective' probabilities of trial outcomes and on the value that parents

and patient-participant place on those outcomes³². Also in our study, the main reason for parents to participate in the BeSt for Kids study was to support the best interest of their child (theme 3). For some parents, the trial represented the prospect of receiving a new, not routinely available treatment with a potentially important direct benefit to their child as was recognized previously as an important motivator for parents and patients to participate in studies^{33,30}. Etanercept is in the Netherlands not reimbursed as first treatment option. Therefore, as initial treatment, it was only available within the trial and parents may consent to their child's entry because of the chance of receiving these assumed benefits^{34,30}. It may cause them firstly to anticipate remorse for not at least trying to obtain this new treatment through trial participation, and secondly to expect consequences when withdrawing during the study. This is understandable from their perspective as guardian of the interests of their child¹². One could imagine a different outcome in cases where parents prefer a standard treatment which is routinely available outside of research. Additionally, a short course of Prednisolone is regularly applied in daily patient care in Juvenile idiopathic arthritis patients as bridging therapy, since methotrexate is a slow-acting DMARD.

Whatever trial strategy parents think is better for their child, their preference shows that the idea of clinical equipoise held by the expert medical community is not directly transferable to the parent setting as a proxy³⁵. For parents and children the different strategies of a trial are often not in equipoise, because they hold the conviction that one strategy is medically superior^{33,34,36}. Although in this study many parents, but not all, were prepared to enter a study (and continue participation) when they had preferences for therapy other than what they received, this lack of equipoise could be a major problem for recruitment in RCT's.

The question is whether the absence of equipoise in parents and patient-participants indicates that randomization is unethical. Some authors state that participation is not permissible when there is no patient-participant equipoise⁹. We however argue that equipoise is based on 2 obligations: 1) a clinical obligation, which contains a) a scientific and b) a therapeutic part. The therapeutic obligation (1b) means that children should not be randomized to inferior treatments at least in studies with more than minimal risks. This is an obligation of the medical community which is not influenced by parental or child preferences; the scientific obligation (1a) means there are clear epistemic reasons to conduct a randomized clinical trial to acquire robust data. This *is* influenced by parental or child preferences, especially when families withdraw their consent due to a preference and thereby introduce bias. 2) an ethical obligation i.e. patient-participants and parents should be well informed on the experimental nature of the study and should understand the aim of the study. They should also understand the scientific consequences (limited resources, inefficiency in the study, possible loss of trust in medical research) to the trial when withdrawing if not randomized in the preferred strategy.

In this study we evaluated the concept of equipoise by exploring patients' and parents' decisions about whether or not to participate in a trial for a chronic disease and their individual reasons to do so. Viewed that way, patient equipoise is concerned with a "committed personal decision"³⁵ and is an *individual* standard. One could however also imagine an informed *patient group* equipoise, in analogy to equipoise in the expert community (as opposed to individual equipoise of a single researcher or treating physician). What seems to be equally important is that not only the patient group should be informed, but also the researcher, by gathering information on the values and preferences patients have at the start of treatment. This will help to know the patient group as a whole and can facilitate recruitment.

Recently it was suggested by Whybrow³⁵ to take an epidemiological approach to the concept of equipoise situating it as a measurable characteristic of a target patient group. We argue that both types of patient equipoise (individual and group) are relevant at different time points in the clinical research setting. Individual patient equipoise is relevant when actually contemplating trial participation between physician and patient/parent. Individual values need to be discussed and exchanged to explore possible trial participation. Informed group patient equipoise is relevant, and we would say even necessary, in the phase of developing a trial to evaluate whether the research question the physician wants to answer is in line with the preferences of the patient group.

If scientists are aware of the consequences of strong patient preferences by evaluating the patient group equipoise they can anticipate to the possible lack of inclusions in a trial. Vigilance is warranted especially in studies with a placebo-arm since retention in those studies potentially is at risk. One example with a deviating clinical expert equipoise and patient group equipoise is the CONCERT study. *The CONgenital Cmv: Efficacy of antiviral treatment in a Randomized controlled Trial* (CONCERT) study aimed to evaluate the efficacy of antiviral therapy in congenital cytomegalovirus (CMV) infection in a randomized clinical trial (clinical trials.gov NCT01655212). The inclusion period was terminated prematurely due to lack of inclusions since parents did not want to randomize for placebo treatment (personal communication). The study design was changed to an efficacy study with a historical control group. 'Placebo' versus 'treatment' is different from 3 different treatment strategies. Therefore every particular study design may need a different approach in case of lacking equipoise on the level of the informed patient group. Preferably the informed patient group is involved early in the study design to prevent lack of inclusion in studies. As an example, the future research agenda in JIA will be created according to the James Lind Alliance method³⁷, to create research that really matters to parents/patients and caregivers and this will potentially increase enrolment in future studies.

CONCLUSION

Parental and patient equipoise is important to investigate to enhance recruitment for and retention in studies involving children. In our study, lack of equipoise during enrolment did not reduce study recruitment, due to the fact that preferred treatment was only available within the study. Still, when developing a trial it is important to evaluate whether the research question the physicians want to answer is in line with the preferences of the patient group. By exploring 'informed patient-group' equipoise successful recruitment may be enhanced and bias may be avoided.

Lack of equipoise during participation in our long term follow-up trial did not reduce retention in those who were assigned to a less favoured option. We observed a change for preference towards treatment actually received, possibly explained by favourable outcomes in all three arms³⁸.

REFERENCES

1. Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med*. 1987;317(3):141-5. doi:10.1056/NEJM198707163170304 [doi].
2. Rodrigues HC, Oerlemans AJ, van den Berg PP. The need for uncertainty in clinical research. *Equipoise*. *Ned Tijdschr Geneeskd*. 2011;155(49):A3846.
3. van der Graaf R, van Delden JJ. Equipoise should be amended, not abandoned. *Clin Trials*. 2011;8(4):408-16. doi:1740774511409600 [pii];10.1177/1740774511409600 [doi].
4. Greisen G, van Bel F. Equipoise is necessary for randomising patients to clinical trials. *Acta Paediatr*. 2016;105(11):1259-60. doi:10.1111/apa.13549.
5. Miller FG. Is anything lost if we give up clinical equipoise? *Clin Trials*. 2012;9(5):632-3. doi:10.1177/1740774512455262.
6. Wendler D, Rid A. In Defense of a Social Value Requirement for Clinical Research. *Bioethics*. 2017;31(2):77-86. doi:10.1111/bioe.12325.
7. Kimmelman J. The social function of clinical equipoise. *Clin Trials*. 2012;9(5):630-1. doi:10.1177/1740774512455261.
8. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. *N Engl J Med*. 2011;364(5):476-80. doi:10.1056/NEJMs1011301 [doi].
9. Veatch RM. Indifference of subjects: an alternative to equipoise in randomized clinical trials. *Soc Philos Policy*. 2002;19(2):295-323.
10. Garcia J, Elbourne D, Snowdon C. Equipoise: a case study of the views of clinicians involved in two neonatal trials. *Clin Trials*. 2004;1(2):170-8. doi:10.1191/1740774504cn020xx.
11. Braga LH, Bagli DJ, Lorenzo AJ. Placebo-controlled trials in pediatric urology: a cautionary view from an ethical perspective. *J Pediatr Urol*. 2010;6(5):435-42. doi:10.1016/j.jpuro.2010.02.208.
12. de Vries MC, Houtlosser M, Wit JM, Engberts DP, Bresters D, Kaspers GJ et al. Ethical issues at the interface of clinical care and research practice in pediatric oncology: a narrative review of parents' and physicians' experiences. *BMC Med Ethics*. 2011;12:18. doi:1472-6939-12-18 [pii];10.1186/1472-6939-12-18 [doi].
13. Byrne-Davis LM, Salmon P, Gravenhorst K, Eden TO, Young B. Balancing high accrual and ethical recruitment in paediatric oncology: a qualitative study of the 'look and feel' of clinical trial discussions. *BMC Med Res Methodol*. 2010;10:101. doi:10.1186/1471-2288-10-101.
14. Hugle B, Haas JP, Benseler SM. Treatment preferences in juvenile idiopathic arthritis- a comparative analysis in two health care systems. *Pediatr Rheumatol Online J*. 2013;11(1):3. doi:10.1186/1546-0096-11-3.
15. Burnett HF, Regier DA, Feldman BM, Miller FA, Ungar WJ. Parents' preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment. *Arthritis Care Res (Hoboken)*. 2012;64(9):1382-91. doi:10.1002/acr.21698.
16. Chau K, Koren G. The principle of equipoise in pediatric drug trials. *Paediatr Drugs*. 2015;17(1):17-21. doi:10.1007/s40272-014-0105-1.
17. Shilling V, Young B. How do parents experience being asked to enter a child in a randomised controlled trial? *BMC Med Ethics*. 2009;10:1. doi:10.1186/1472-6939-10-1.
18. van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. *Ann Rheum Dis*. 2007;66(11):1518-24. doi:ard.2006.064717 [pii];10.1136/ard.2006.064717 [doi].
19. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. *N Engl J Med*. 1992;326(16):1043-9. doi:10.1056/nejm199204163261602.

20. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. *Arthritis Rheum.* 2003;48(1):218-26. doi:10.1002/art.10710 [doi].
21. Malterud K. Qualitative research: standards, challenges, and guidelines. *Lancet.* 2001;358(9280):483-8. doi:S0140-6736(01)05627-6 [pii];10.1016/S0140-6736(01)05627-6 [doi].
22. Strauss AL CJ. *Basics of qualitative research: techniques and procedures for developing grounded theory.* Sage publications, London; 1998.
23. Guest G, A B, L J. How many interviews are enough? An experiment with data saturation and variability 2006. Report No.: 18 (1).
24. NK D, Y L. *Handbook of qualitative research.* Thousand oaks, Sage publications; 2000.
25. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. *Pediatric Rheumatology Collaborative Study Group. N Engl J Med.* 2000;342(11):763-9.
26. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum.* 2006;54(6):1987-94. doi:10.1002/art.21885 [doi].
27. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. *Arthritis Rheum.* 2009;60(9):2794-804. doi:10.1002/art.24777 [doi].
28. Prince FH, Twilt M, ten CR, van Rossum MA, Armbrust W, Hoppenreijns EP et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. *Ann Rheum Dis.* 2009;68(5):635-41. doi:ard.2007.087411 [pii];10.1136/ard.2007.087411 [doi].
29. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). *Ann Rheum Dis.* 2007;66(9):1227-32. doi:ard.2006.068296 [pii];10.1136/ard.2006.068296 [doi].
30. Tromp K, Zwaan CM, van de Vathorst S. Motivations of children and their parents to participate in drug research: a systematic review. *Eur J Pediatr.* 2016;175(5):599-612. doi:10.1007/s00431-016-2715-9.
31. Hoberman A, Shaikh N, Bhatnagar S, Haralam MA, Kearney DH, Colborn DK et al. Factors that influence parental decisions to participate in clinical research: consenters vs nonconsenters. *JAMA Pediatr.* 2013;167(6):561-6. doi:10.1001/jamapediatrics.2013.1050.
32. Lilford RJ. Ethics of clinical trials from a bayesian and decision analytic perspective: whose equipoise is it anyway? *BMJ.* 2003;326(7396):980-1. doi:10.1136/bmj.326.7396.980 [doi];326/7396/980 [pii].
33. Kupst MJ, Patenaude AF, Walco GA, Sterling C. Clinical trials in pediatric cancer: parental perspectives on informed consent. *J Pediatr Hematol Oncol.* 2003;25(10):787-90.
34. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. *SocSciMed.* 1997;45(9):1337-55. doi:S0277953697000634 [pii].
35. Alderson P. Equipoise as a means of managing uncertainty: personal, communal and proxy. *J Med Ethics.* 1996;22(3):135-9.
36. Eiser C, Davies H, Jenney M, Glaser A. Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children. *Child Care Health Dev.* 2005;31(5):517-23. doi:CCH538 [pii];10.1111/j.1365-2214.2005.00538.x [doi].
37. Schoemaker CG, Armbrust W, Swart JF, Vastert SJ, van Loosdregt J, Verwoerd A et al. Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol. *Pediatr Rheumatol Online J.* 2018;16(1):57. doi:10.1186/s12969-018-0276-3.
38. Hissink Muller PCE, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, Bekkering WP, Kuijpers TW, van Rossum MAJ, van Suijlekom-Smit LWA, van den Berg JM, Boehringer S, Allaart CF, ten Cate R. Treat to target (drug-free) inactive disease in DMARD naive Juvenile Idiopathic Arthritis: 24-months clinical outcomes of a three-armed randomised trial. *Annals of Rheumatic Diseases.* 2018. doi:10.1136/annrheumdis-2018-213902.

SUPPLEMENTARY FILE 1

The three treatment strategies in the BeSt for Kids study

arm 1 Sequential Monotherapy	arm 2 Combination MTX + 6 wks prednisone	arm 3 Combination etanercept and MTX
<p>MTX 10 mg/m²/wk po/sc Alternative: SSZ 50 mg/kg/day po</p> <p>↓</p> <p>MTX 10 mg/m²/wk po/sc</p> <p>↓</p> <p>MTX 15 mg/m²/wk po/sc</p> <p>↓</p> <p>MTX 10 mg/m²/wk po/sc + ETN 0.8 mg/kg/wk (max. 50 mg)</p> <p>↓</p> <p>MTX 10 mg/m²/wk + ETN 1.6 mg/kg/wk (max. 50 mg)</p> <p>↓</p> <p>Treatment left to treating physician</p>	<p>MTX 10 mg/m²/wk po/sc + pred 0.5 mg/kg/day tapered to 0</p> <p>↓</p> <p>MTX 15 mg/m²/wk po/sc</p> <p>↓</p> <p>MTX 10 mg/m²/wk po/sc + ETN 0.8 mg/kg/wk</p> <p>↓</p> <p>MTX 10 mg/m²/wk + ETN 1.6 mg/kg/wk</p> <p>↓</p> <p>Treatment left to treating physician</p>	<p>MTX 10 mg/m²/wk po/sc + ETN 0.8 mg/kg/wk</p> <p>↓</p> <p>MTX 10 mg/m²/wk + ETN 1.6 mg/kg/wk</p> <p>↓</p> <p>Treatment left to treating physician</p>

MTX=methotrexate, SSZ=Sulphasalazine, ETN=etanercept, Po=orally, Sc=subcutaneous

SUPPLEMENTARY FILE 2

Questionnaire during enrolment BeSt for Kids study (Translated from Dutch)

This questionnaire is concerning satisfaction of patient and/or his/her parents with the treatment in the study.

Your child/you are participating in the BeSt for Kids study, a study in search for the optimal treatment strategy in patients diagnosed with juvenile idiopathic arthritis.

What we do not know yet, is, if you as patient and parents have a preference for one of the different strategies in the BeSt for Kids study. Because your preference is also very important, we would like to investigate this. Your opinion could be of significant influence on future treatment of patients with juvenile idiopathic arthritis.

Background information:

Patients recently diagnosed with juvenile idiopathic arthritis are treated with anti-rheumatic drugs.

Frequently treatment is started with one medicine, sulfasalazine or methotrexate. If this medicine is not effective enough, treatment is changed to the next anti-rheumatic drug. However, some indications show that direct treatment with a combination of anti-rheumatic drugs could be more successful. Besides that, since some time a new medicine is available administered by injection, etanercept (Enbrel), which is clearly beneficial in patients with chronic, severe juvenile arthritis not responding to traditional treatment.

What was the treatment group that you **do** hoped to be allotted to?

- No
- Yes we hoped to be allotted to arm 1
- Yes we hoped to be allotted to arm 2
- Yes we hoped to be allotted to arm 3

What was the treatment group that you hoped **not** to be allotted to?

- No
- Yes we hoped not to be allotted to arm 1
- Yes we hoped not to be allotted to arm 2
- Yes we hoped not to be allotted to arm 3

SUPPLEMENTARY FILE 3

Relevant information from parental informed consent brochure

Why this study

The goal of this study is to determine which of three treatment strategies is the best for a child with oligo or polyarticular juvenile idiopathic arthritis.

It is not the point which individual medication is superior but we want to compare if it is better to give the medication one after another or to start with a combination or directly with maximum treatment. This comparison is relevant to study if early aggressive treatment is better able to prevent joint damage in the future. At the moment we cannot predict the course of the disease in an individual patient.

We know that if a child has only a few or even one joint with arthritis (oligoarticular course) at the start of disease, problems later in life can be comparable with a child with many joints with arthritis at the start (polyarticular course). Maybe it is superior to treat the disease from the start maximally and then, if all arthritis is over, taper medication.

All medication used in this study is already in use in the treatment of children with juvenile arthritis.

What does the study entail?

If you decide to participate in the study your child will be randomized in one of the following 3 options:

Option 1: treatment with antirheumatic drugs sequentially until arthritis is over. The first medicine is named sulfasalazine or methotrexate (tablets, first low dose, later high dose if necessary) and the third medicine is etanercept (administered through an injection, first normal dose, possible higher dose later)

Option 2: the antirheumatic drug methotrexate is combined with prednisolone and if this is not sufficient or in case of (severe) side effects treatment is changed to etanercept.

Option 3: etanercept is started directly combined with methotrexate.

Risks and concerns

There are pros and cons to each of the three treatments strategies mentioned. In short, the most experience exists with the first and second option. The medication has been known for a long time, so the short and long term effects and adverse effects are known. From the third treatment strategy we know that it can quickly have a good effect on children

with juvenile arthritis, especially when many joints are involved in inflammation. The side effects of this treatment on the long-term are not well known yet, but by stopping the medication soon after joint inflammation disappears, the child is exposed relatively short.

SUPPLEMENTARY FILE 4

Questionnaire Informed Consent Evaluation BeSt for Kids

1. General questions and demographic information

1. Sex patient
 Male Female

2. Date of birth patient:

3. Date of birth parents:
Father:
Mother:

4. Place of residency of patient and family

5. Composition of the family
 Only child
 Brothers and sisters, that is

 Parents together
 Parents divorced

6. Working Activities of parents:
Father:
Mother:

7. Highest education level father :
Primary school / lower level high school
Middle level high school
Advanced vocational / university

8. Highest education level mother:
Primary school / lower level high school
Middle level high school
Advanced vocational / university

9. Nationality parents:
 Dutch
 Other, that is,.....

10. Religion of parents
 Christianity
 Jewish
 Islam
 No religion
 Other, that is....

2. Retainment of information concerning the trial

1. What trial is your child participating in?
 - a. BeSt for Kids
 - b. Rheumatism for Kids
 - c. JIA for Kids
 - d. I don't know

2. What is the goal of the trial?
 - a. To test new medication for children with certain types of Juvenile Idiopathic Arthritis
 - b. To investigate the best treatment strategy from three possibilities for children with certain types of juvenile idiopathic arthritis
 - c. To research what particular drug is the best treatment for children with JIA
 - d. I don't know

3. How many strategies exist in the trial
 - a. 5
 - b. 3
 - c. 4
 - d. I don't know

4. Who decided which strategy your child received?
 - a. The treating physician
 - b. This was assigned by lot
 - c. The principal investigator
 - d. I don't know

5. Have you been informed about risks concerning trial participation, and if yes what risks?

6. Have you been informed about benefits of trial participation, and if yes what benefits?

7. Are there any extra procedures (like blooddraws, visits to the outpatient clinic) that your child would not receive if not participating in the trial?

8. What is the duration of the trial?
 - a. 1 year
 - b. 2 years
 - c. 3 years
 - d. I don't know

9. Are data of your child preserved?
 - a. Yes
 - b. Yes, as long as permission was given
 - c. No
 - d. I don't know

10. Is the treating physician aware of the treatment strategy of your child?
 - a. No this is a blinded trial
 - b. Yes the physician is informed
 - c. I don't know

11. Are you allowed to withdraw at all times from the trial?
 - a. Yes
 - b. No
 - c. I don't know

12. Does this have consequences for the treatment of your child?
 - a. Yes
 - b. No
 - c. I don't know

13. Is it possible to discuss issues with an independent physician?
 - a. Yes
 - b. No
 - c. I don't know

14. If yes, do you know who it is?
 - a. No I don't know
 - b. Yes, that is.....

15. Did you understand the provided information at that time?
 - a. es it was clear
 - b. Yes after extra verbal explanation
 - c. No it was not clear
 - d. I don't know

16. Have you been asked if everything was clear to you?
 - a. Yes
 - b. No
 - c. I don't know

17. Did you have enough time to answer questions?
 - a. Yes
 - b. No

18. Did you receive information to take home?
 - a. Yes
 - b. No
 - c. I don't know

19. Was this information sufficient?
 - a. Yes
 - b. Too much information
 - c. Too little information

20. Did you experience enough time to think about participation in the trial?
 - a. Yes, enough
 - b. Yes but could have been more
 - c. No, not enough

21. Who finally decided to participate in the trial?
 - a. the physician
 - b. the physician and parents
 - c. the physician, parents and patient
 - d. the parents
 - e. the parents and patient

3. The next questions are to increase our perception of your considerations regarding the treatment

1. What was your preferred strategy at the moment of trial inclusion?
In other words: did you wish your child to be assigned to a particular treatment strategy?
2. Can you explain why?
3. What is your preferred strategy now?
4. Can you explain why?
5. Are you satisfied with the given treatment?
6. To your opinion, did the physician have a preferred strategy?

4. Suggestions for improvement and questions

1. What was your impression of the conversation about trial participation of your child?
2. Are you satisfied with the communication with the physician during the process towards participation in the trial?
3. What was your main reason for participation in the trial?
4. Would you like to stay informed about the results of the trial?
5. Do you have suggestions for improvement of the informed consent procedure?
6. Do you have any more questions or remarks?

SUPPLEMENTARY FILE 5

Table 2 | Parent preferences at inclusion (phase 1) and during interview (phase 2), in relation to actual enrolled treatment strategy

Parent number	Preferred strategy at inclusion (phase 1)	Actual Treatment strategy	Preferred Strategy during interview (phase 2)	Change of preference To actual treatment strategy	Change of preference to Arm 3
1	2	1	1	X	
2	No preference	2	3		X
3	3	3	3		
4	No preference	2	2	X	
5	2	2	2		
6	No preference	3	3	X	X
7	3	1	3		
8	3	1	3		
9	1	1	3		X
10	No preference	3	1		
11	3	1	3		
12	3	3	3		
13	3	1	1	X	
14	3	1	3		
15	3	1	1	X	
16	No preference	3	3	x	X
17	No preference	1	1	X	
18	3	3	3		
19	No preference	2	1		
20	3	3	3		
21	No preference	3	1		
22	3	2	3		
23	3	1	3		

Table 3 | Summary of initial preferences (phase 1), actual enrolled arm and preference during the interview (phase 2). NA = not applicable

	No preference	Arm 1	Arm 2	Arm 3
Initial preference (phase 1)	8	1	2	12
Actual treatment strategy	NA	10	5	8
Preference during interview (phase 2)				
Compatible with actual treatment strategy	0	7	2	14
		4	2	6

